Latest & greatest articles for estradiol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on estradiol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on estradiol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for estradiol

1. Segesterone acetate and ethinyl estradiol vaginal system (Annovera) - New vaginal ring used to prevent pregnancy for an entire year

Segesterone acetate and ethinyl estradiol vaginal system (Annovera) - New vaginal ring used to prevent pregnancy for an entire year Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol) Company: The Population Council, Inc. Application Number: 209627 Approval Date: 08/10/2018 Persons with disabilities having problems accessing

FDA - Drug Approval Package2018

2. A 17beta-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial

A 17beta-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial 29889748 2018 06 29 1873-233X 132 1 2018 Jul Obstetrics and gynecology Obstet Gynecol A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. 161-170 10.1097/AOG.0000000000002645 To evaluate efficacy, endometrial safety, and overall safety of a single-capsule 17β-estradiol-progesterone (TX-001HR) for treating (...) menopausal moderate-to-severe vasomotor symptoms. REPLENISH was a phase 3, 12-month, randomized, double-blind, placebo-controlled, multicenter trial. Women (aged 40-65 years) with vasomotor symptoms and a uterus were randomized to daily estradiol (mg)-progesterone (mg) (1/100, 0.5/100, 0.5/50, or 0.25/50), and women in the vasomotor symptoms substudy (women with moderate-to-severe hot flushes [seven or greater per day or 50 or greater per week]) to those estradiol-progesterone doses or placebo

EvidenceUpdates2018

3. Estradiol

Estradiol Top results for estradiol - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for estradiol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

4. Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men

Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men 30057969 2018 11 14 2472-1972 2 8 2018 Aug 01 Journal of the Endocrine Society J Endocr Soc Estradiol Does Not Influence Lipid Measures and Inflammatory Markers in Testosterone-Clamped Healthy Men. 882-892 10.1210/js.2018-00141 Experimentally controlled studies of estrogenic regulation of lipid measures and inflammatory cytokines in men are rare. To delineate the effect of estradiol (E 2 (...) NIDDK NIH HHS United States Journal Article 2018 06 29 United States J Endocr Soc 101697997 2472-1972 age estradiol human inflammation lipids testosterone 2018 05 10 2018 06 26 2018 7 31 6 0 2018 7 31 6 0 2018 7 31 6 1 epublish 30057969 10.1210/js.2018-00141 js_201800141 PMC6055532 J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8 15240608 J Clin Endocrinol Metab. 1994 Apr;78(4):855-61 8157711 Endocr J. 1993 Oct;40(5):507-13 7951516 J Clin Endocrinol Metab. 2005 Jan;90(1):211-8 15483079 J Pharmacokinet

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

5. Differential Effects of Estradiol and Progesterone on Cardiovascular Risk Factors in Postmenopausal Women

Differential Effects of Estradiol and Progesterone on Cardiovascular Risk Factors in Postmenopausal Women 29978153 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Differential Effects of Estradiol and Progesterone on Cardiovascular Risk Factors in Postmenopausal Women. 794-805 10.1210/js.2018-00073 Controlled, blinded studies of sex-hormone replacement in postmenopausal women using natural estradiol (E 2 ) and native progesterone (P) are few. To delineate

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

6. Hormonal Treatment of Transgender Women with Oral Estradiol

Hormonal Treatment of Transgender Women with Oral Estradiol 29756046 2018 11 14 2380-193X 3 1 2018 Transgender health Transgend Health Hormonal Treatment of Transgender Women with Oral Estradiol. 74-81 10.1089/trgh.2017.0035 Purpose: Maintaining cross-sex hormone levels in the normal physiologic range for the desired gender is the cornerstone of transgender hormonal therapy, but there are limited data on how to achieve this. We investigated the effectiveness of oral estradiol therapy (...) in achieving this goal. Methods: We analyzed data on all transgender females seen in our clinic since 2008 treated with oral estradiol. We looked at the success of achieving serum levels of testosterone and 17-β estradiol in the normal range on various doses of estradiol (with and without antiandrogens spironolactone and finasteride). Results: There was a positive correlation between estradiol dose and 17-β estradiol, but testosterone suppression was less well correlated. Over 70% achieved treatment goals

Transgender health2018 Full Text: Link to full Text with Trip Pro

7. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial

Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial 29554173 2018 04 19 2168-6114 2018 Mar 19 JAMA internal medicine JAMA Intern Med Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. 10.1001/jamainternmed.2018.0116 Nearly half of postmenopausal women report bothersome vulvovaginal symptoms, but few data support (...) the efficacy of 2 commonly recommended treatments. To compare the efficacy of a low-dose vaginal estradiol tablet and a vaginal moisturizer, each vs placebo, for treatment of moderate-to-severe postmenopausal vulvovaginal symptoms. This 12-week multicenter randomized clinical trial enrolled postmenopausal women with moderate to severe symptoms of vulvovaginal itching, pain, dryness, irritation, or pain with penetration. Vaginal 10-μcg estradiol tablet (daily for 2 weeks, then twice weekly) plus placebo gel

EvidenceUpdates2018

8. 17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes

17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes ISSN 2472-1972 17b-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes Fatou Jallow, 1,2 Jennifer L. Brockman, 2 Kyle T. Helzer, 3 Debra E. Rugowski, 2 Vincent Goffin, 4 Elaine T. Alarid, 3,5 and Linda A. Schuler 2,5 1 Endocrinology/Reproductive Physiology Program, University of Wisconsin-Madison, Madison (...) regulate gene expression in breast cancer cells in vitro. Canonical PRL signaling activates STAT5A/B, homologous proteins that have different target genes and functions. Although STAT5A/B are important for physiological mammary function and tumor pathophysiology, little is known about regulationoftheirexpression,particularlyofSTAT5B,andtheconsequencesforhormoneaction.Inthis study,weexaminedtheeffectoftwoestrogenicligands,17b-estradiol(E2)andtheclinicalantiestrogen, ICI182,780 (ICI, fulvestrant

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

9. 17β-Estradiol Promotes Islet Cell Proliferation in a Partial Pancreatectomy Mouse Model

17β-Estradiol Promotes Islet Cell Proliferation in a Partial Pancreatectomy Mouse Model 29264547 2018 11 13 2472-1972 1 7 2017 Jul 01 Journal of the Endocrine Society J Endocr Soc 17 β -Estradiol Promotes Islet Cell Proliferation in a Partial Pancreatectomy Mouse Model. 965-979 10.1210/js.2016-1073 17 β -Estradiol (E2) is a multifunctional steroid hormone in modulating metabolism in vivo . Previous studies have reported that E2 could promote insulin secretion and protect β cells from apoptosis (...) , Anhui Medical University, Hefei, Anhui 230032, China. Ren Zhenhua Z Department of Neurobiology, School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, China. Department of Anatomy, School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, China. Cell Therapy Center, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. eng Journal Article 2017 06 05 United States J Endocr Soc 101697997 2472-1972 17β-Estradiol cell proliferation diabetes mellitus islet

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

10. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis

Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis 27421538 2016 08 16 2017 02 20 1526-632X 87 7 2016 Aug 16 Neurology Neurology Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. 699-708 10.1212/WNL.0000000000002980 To test the hypothesis that effects of estrogen-containing hormone therapy on cognitive abilities differ between postmenopausal women near to, and further from, menopause. In this randomized, double (...) -blind, placebo-controlled trial, healthy women within 6 years of menopause or 10+ years after menopause were randomly assigned to oral 17β-estradiol 1 mg/d or placebo. Women with a uterus received cyclic micronized progesterone vaginal gel or placebo. The primary outcome assessed at 2.5 and 5 years, compared between treatment groups, was change in a standardized composite of neuropsychological test scores assessing verbal episodic memory. Secondary outcomes assessed executive functions and global

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

11. Estradiol immunoassays ? interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results

Estradiol immunoassays ? interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results Estradiol immunoassays – interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results - GOV.UK GOV.UK uses cookies to make the site simpler. Search Estradiol immunoassays – interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results From: Published: 24 March 2016 Issued: 24 March 2016 Alert type: Medical (...) specialism: Manufactured by Siemens Healthcare Diagnostics Inc. / Siemens Healthcare Diagnostics Ltd and Roche Diagnostics GmbH- assay interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results. Both Siemens and Roche have issued field safety notices (FSNs) highlighting this issue. Estradiol assays from other manufacturers may also be affected by fulvestrant (Faslodex®) interference and this is currently under investigation (MDA/2016/004). Contents Action Action

MHRA Drug Safety Update2016

12. Postmenopausal Breast Cancer Risk in Relation to Antibodies Specific to Benzo[a]Pyrene, Estradiol and Progesterone

Postmenopausal Breast Cancer Risk in Relation to Antibodies Specific to Benzo[a]Pyrene, Estradiol and Progesterone 27482331 2016 08 02 2018 11 13 2008-2398 9 2 2016 Apr Iranian journal of cancer prevention Iran J Cancer Prev Postmenopausal Breast Cancer Risk in Relation to Antibodies Specific to Benzo[a]Pyrene, Estradiol and Progesterone. e4212 10.17795/ijcp-4212 Antibodies might protect against low doses of environmental carcinogens by decreasing systemic uptake, activation of metabolic (...) pathways, and redistribution of carcinogens within the organism. The features of antibody formation in relation to environmental carcinogens and sex steroids under natural conditions should be determined to identify breast cancer risk, then to develop cancer immune prevention strategies. The purpose of this study was to investigate antibodies specifications to benzo(a)pyrene, estradiol and progesterone in postmenopausal women with invasive breast cancer. A semi-quantitative non-competitive immunoassay

Iranian journal of cancer prevention2016 Full Text: Link to full Text with Trip Pro

13. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. BACKGROUND: Data suggest that estrogen-containing hormone therapy is associated with beneficial effects with regard to cardiovascular disease when the therapy is initiated temporally close to menopause but not when it is initiated later. However, the hypothesis that the cardiovascular effects of postmenopausal hormone therapy vary with the timing of therapy initiation (the hormone-timing hypothesis) has not been (...) tested. METHODS: A total of 643 healthy postmenopausal women were stratified according to time since menopause (<6 years [early postmenopause] or ≥10 years [late postmenopause]) and were randomly assigned to receive either oral 17β-estradiol (1 mg per day, plus progesterone [45 mg] vaginal gel administered sequentially [i.e., once daily for 10 days of each 30-day cycle] for women with a uterus) or placebo (plus sequential placebo vaginal gel for women with a uterus). The primary outcome

NEJM2016 Full Text: Link to full Text with Trip Pro

14. Nomegestrol acetate / estradiol (Zoely) - Oral contraception

Nomegestrol acetate / estradiol (Zoely) - Oral contraception Published 08 July 2013 Statement of Advice: nomegestrol acetate/estradiol (Zoely ®) 2.5 mg/1.5 mg film-coated tablets (No: 898/13) Merck Sharp & Dohme Limited 07 June 2013 ADVICE: in the absence of a submission from the holder of the marketing authorisation nomegestrol acetate/estradiol (Zoely®) is not recommended for use within NHS Scotland. Indication under review: Oral contraception. The holder of the marketing authorisation has

Scottish Medicines Consortium2013

15. NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring

NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring Drug Approval Package: NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring Company: Organon USA Inc. Application No.: 021187s021s022 Approval Date: 10/04/2013 Persons

FDA - Drug Approval Package2013

16. Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets)

Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets) Company: Warner Chilcott Company, LLC Application No.: 204654 Approval

FDA - Drug Approval Package2013

17. Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets

Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets Drug Approval Package: Norethindrone Acetate and Ethinyl Estradiol NDA #203667 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets Company: Warner Chilcott Company, LLC Application No.: 203667 Approval Date: 05/08/2013 Persons with disabilities having problems accessing

FDA - Drug Approval Package2013

18. Combined oral contraception: nomegestrol/estradiol (Zoely)

Combined oral contraception: nomegestrol/estradiol (Zoely) Combined or Combined oral contr al contraception: nomegestrol/ aception: nomegestrol/ estr estradiol (Z adiol (Zoely) oely) Evidence summary Published: 17 December 2013 nice.org.uk/guidance/esnm28 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) websites for up-to-date information. Summary Nomegestrol/estradiol (Zoely) has similar contraceptive efficacy to drospirenone/ethinylestradiol (Yasmin) with similar numbers of days of unscheduled bleeding, fewer days of withdrawal bleeding and significantly more absence of withdrawal bleeding. Acne and weight gain were reported more frequently in women taking nomegestrol/estradiol than in women taking drospirenone/ ethinylestradiol (statistical significance not reported). © NICE 2018. All rights

National Institute for Health and Clinical Excellence - Advice2013

19. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI.

Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. ACP Journal Club. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My (...) Bibliography Citation manager Format Create File 1 selected item: 23070511 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Oct 16;157(8):JC4-9. doi: 10.7326/0003-4819-157-8-201210160-02009. ACP Journal Club. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. . Comment on [N Engl J

Annals of Internal Medicine2012

20. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial

Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial 22055339 2012 01 30 2012 07 19 2016 12 15 1097-6868 206 2 2012 Feb American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. 129.e1-8 10.1016/j.ajog.2011.09.021 The purpose of this study was to evaluate whether oral naproxen or transdermal (...) estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system. We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use. Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis. There were 129 women who were assigned randomly to naproxen (n = 42 women), estradiol (n

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro